Skip to main content

Immunobiology and immunotherapy

Section edited by Alessandra Cesano

This section aims to enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

As immunology has evolved to be a central discipline connected to a wide range of therapeutic areas, the number and diversity of platform technologies has also increased, spanning small molecules, biologics, microbial vectors and cells. Such levels of activity require appropriate means to share new knowledge and to catalyze the development of the field. This section aims to provide such a platform and welcomes submissions across all disciplines, including inflammation, autoimmunity, transplantation, metabolic disorders.

The section was founded with the Society for Immunotherapy of Cancer (SITC) under the title "Tumor immunology and biological cancer therapy" and Edited by Pedro Romero.

Page 8 of 8

  1. Liposomal doxorubicin (Doxil) is a cytotoxic chemotherapy drug with a favorable hematologic toxicity profile. Its active drug, doxorubicin, has interesting immunomodulatory properties. Here, the effects of Dox...

    Authors: Ioannis Alagkiozidis, Andrea Facciabene, Carmine Carpenito, Fabian Benencia, Zdenka Jonak, Sarah Adams, Richard G Carroll, Phyllis A Gimotty, Rachel Hammond, Gwen-äel Danet-Desnoyers, Carl H June, Daniel J Powell Jr and George Coukos

    Citation: Journal of Translational Medicine 2009 7:104

    Content type: Research

    Published on:

  2. CD40 activation of antigen presenting cells (APC) such as dendritic cells (DC) and B cells plays an important role in immunological licensing of T cell immunity. Agonist CD40 antibodies have been previously sh...

    Authors: Erica L Carpenter, Rosemarie Mick, Jens Rüter and Robert H Vonderheide

    Citation: Journal of Translational Medicine 2009 7:93

    Content type: Research

    Published on:

Annual Journal Metrics